FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: November 10, 2021
Lithium imaging method could shine new light on bipolar disorder, treatment
ACS Central Science
Since 1949, lithium has been a mainstay for treating bipolar disorder (BD), a mental health condition marked by extreme mood swings. But scientists still don鈥檛 have a clear understanding of how the drug works, or why some patients respond better than others. Now, researchers reporting in ACS Central Science developed a method for imaging lithium in living cells, allowing them to discover that neurons from BD patients accumulate higher levels of lithium than healthy controls.
According to the National Institutes of Health, 4.4% of U.S. adults experience BD at some time in their lives. Studies have shown that lithium-based drugs can help stabilize mood and reduce suicide risk in people with BD. However, only about one-third of BD patients respond completely to lithium treatment, and the rest respond only partially or not at all. One reason could be that the drug has an extremely narrow therapeutic range: Below a certain blood serum level of lithium, most patients do not respond, but at a slightly higher level, they can experience severe side effects. Being able to measure lithium concentrations directly in a patient鈥檚 neurons could help scientists understand how lithium works as a drug, and then they could use this knowledge to optimize the dosage. So Yi Lu and colleagues wanted to develop a method to detect and measure lithium in living cells at therapeutically relevant concentrations.
The researchers used in vitro selection to identify a DNA enzyme (DNAzyme) that catalyzes the release of a fluorescent molecule from an RNA probe, thus producing a signal, only when lithium is present. The DNAzyme was 100 times more selective for lithium over other metal ions, and it was sensitive enough to detect lithium at concentrations within the therapeutic range. As a proof of concept, the researchers collected skin cells from BD patients and healthy donors, reprogrammed them to become stem cells and then differentiated them into neurons. The team treated the neurons with the DNAzyme-based sensor and a therapeutically relevant dosage of lithium. Using fluorescence microscopy, the researchers found that immature neurons from BD patients and healthy controls accumulated similar levels of lithium, but mature neurons from BD patients accumulated higher levels of lithium than mature control neurons. The new lithium sensor is a powerful tool to better understand the effects of lithium in treating BD, the researchers say.
The authors acknowledge funding from the .
###
The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical聽Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical 中国365bet中文官网 (ACS) es una organizaci贸n sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformaci贸n del poder de la qu铆mica. Su misi贸n es promover el conocimiento cient铆fico, empoderar a la comunidad global y defender la integridad cient铆fica, y su visi贸n es un mundo construido bas谩ndose en la ciencia. La Sociedad es l铆der mundial en la promoci贸n de la excelencia en la educaci贸n cient铆fica y en el acceso a informaci贸n e investigaci贸n relacionadas con la qu铆mica a trav茅s de sus m煤ltiples soluciones de investigaci贸n, publicaciones revisadas por expertos, conferencias cient铆ficas, libros electr贸nicos y noticias semanales peri贸dicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las m谩s citadas, las m谩s fiables y las m谩s le铆das en la literatura cient铆fica; sin embargo, la propia ACS no realiza investigaci贸n qu铆mica. Como l铆der en soluciones de informaci贸n cient铆fica, su divisi贸n CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservaci贸n, la conexi贸n y el an谩lisis de los conocimientos cient铆ficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa p煤blicos y retenidos.聽 Para consultas de los medios, comun铆quese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cient铆ficos revisados por expertos.鈥�
;void(0);){kind=link}